In the evolving field of biochemical research and molecular stabilization, the RTP 004 peptide has emerged as a significant point of interest. As someone who follows advancements in peptide technology, I have found the unique structural properties of this compound to be a fascinating study in molecular engineering. It is important to clarify that this d Jun 24, 2023 — DAXI or DAXXIFY, a product of daxibotulinumtoxinA, incorporates RTP004, a proprietary synthetic stabilizing peptide for enhanced product iscussion is for informational purposes, focusing on the biochemical characteristics of this synthetic molecule ra by S Humphrey · 2023 · Cited by 4 — Finally, we found that the presence of binding antibodies to either the core neurotoxin or RTP004 had no impact on the clinical efficacy or duration of DAXI. ther than providing medical advice or human usage instructions.
Structural Composition and Characteristics
The RTP 004 peptide is a specialized, 35-amino acid (5 kDa) protein fragment. Unlike standard peptide chains, this molecule is constructed with two distinct domains, making it Mar 13, 2023 — RTP004 is a small, 35-amino acid (5 kDa) protein fragment (Figure 2).3 The peptide contains 15 consecutive lysines, which are highly positively a highly sophisticated tool for molecular stabilization.
A defining feature of this structure is that RTP 004 is a highly positively charged lysine- and arginine-rich structure. This high positive charge at physiological pH is essential for its function, as it allows the molecule to form strong electrostatic bonds. Researchers have identified this as a novel, 35–amino acid, CPP-containing polypeptide excipient that includes the protein transduction domain sequence from the HIV-1 TAT protein at each end.
The Role of RTP 004 as a Stabilizer
The pri by SF Dowdy · 2023 · Cited by 21 — RTP004 is a highly positively charged lysine- and arginine-rich structure that provides formulation stability, preventing self-aggregation of the cargo mary utility of this compound lies in its role as a proprietary, stabilizing peptide (RTP004). In research settings, RTP 004 stabilizes BoNTA by binding to the core neurotoxin and enhancing its thermostability. By limiting aggregation and preventing surface adsorption, it ensures the structural integrity of the cargo it is designed to protect.
Furthermore, RTP 004 binds by CJ Gallagher · 2023 · Cited by 19 — This evaluation of anti-drug antibody formation with DAXI shows low rates of antibody formation to both daxibotulinumtoxinA and RTP004. to the core neurotoxin and enhances its thermostability, acting in synergy with other stabilizers like polysorbate 20. This combination is highly effective at maintaining the stability of the active complex, which is a significant departure from traditional formulations that rely on human serum albumin.
Mechanism of Action and Interaction
The scientific community has closely studied how this peptide interacts at the cellular level. Evidence suggests that RTP 004 facilitates binding of BoNT/A1 to neuronal membranes and facilitates localization of BoNT/A1 to the neuronal membrane. This interaction is critical because it can increase binding of BoNT-A to the by AF Batista · 2026 — We hypothesized that RTP004 facilitates localization of BoNT/A1 to the neuronal membrane, resulting in increased BoNT internalization and neuronal surface, which in turn influences the efficiency of the overall complex.
Because it is a novel excipient composed of a synthetic peptide, it offers a controlled environm by AF Batista · 2024 · Cited by 8 — The RTP004 peptide can increase binding of BoNT-A to the neuronal surface and increase intracellular SNAP-25 cleavage in a dose-dependent manner. ent for research. One of the most interesting aspects of its behavior is that it dissociates from the neurotoxin at acidic pH levels, similar to the endosomal environment. Additionally, studies Clinical Immunogenicity of DaxibotulinumtoxinA for have noted that the RTP 004 peptide in DAXI reduces the likelihood of antibody formation, which is a key consideration in long-term stability and efficacy studies.
Practical Considerations for Research
When evaluating this technology, it is worth noting that RTP 004 is a 35-amino acid peptide that is transient in biological systems. Specifically, it degrades rapidly in plasma, which makes detection in biological samples quite difficult. This metabolic profile is often highlighted in technical evaluations of the compound.
For those interested in the broader context of these advancements, industry developments—such as products that are powered by Peptide Exchange Technology—continue to push the boundaries of how we stabilize sensitive proteins. While DAXXIFY® is FDA approved for the treatment of cervical dystonia in adults, the underlying science of the excipient peptide, RTP-004, remains a cornerstone of the innovation that allows such complex molecules to remain stable and effective.
Whether you are reviewing the RTP-004 peptide for its unique lysine-rich sequence or its role in membrane binding, it represents a remarkable intersection of chemistry and biotechnology. Understanding these molecular interactions provides a clearer picture of how modern formulations achieve such high levels of precision and stability.